MetaVia Inc. is a clinical-stage biotechnology company developing novel pharmaceuticals for cardiometabolic diseases. The company's lead assets include DA-1241, a GPR119 agonist in Phase 2a testing for metabolic dysfunction-associated steatohepatitis and Phase 1 for type 2 diabetes, and DA-1726, a GLP-1/glucagon receptor dual agonist in Phase 1 development for obesity treatment. The company also maintains a portfolio of earlier-stage programs targeting painful diabetic neuropathy, cognitive impairment, dyslipidemia, and moderate COVID-19.
MetaVia operates through licensing and manufacturing partnerships. The company holds a license agreement with Pfizer for Gemcabene development and commercialization, while Dong-A ST serves as the sole manufacturer for DA-1241 and DA-1726. MetaVia itself is a subsidiary of Dong-A ST, a South Korean pharmaceutical firm that acquired control of the company. Previously operating as NeuroBo Pharmaceuticals, the company rebranded to MetaVia in November 2024 to reflect its strategic focus on metabolic disease treatment.
The company maintains minimal headcount with nine full-time employees and is headquartered in Cambridge, Massachusetts, positioning it within the regional biotechnology cluster. As a clinical-stage entity, MetaVia generates no meaningful revenue from product sales and operates on capital from its parent company and previous funding rounds.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-3.56 | $-3.56 | -44.7% | |
| 2023 | $-2.46 | $-2.46 | +54.7% | |
| 2022 | $-5.43 | $-5.43 | -722.7% | |
| 2021 | $-0.66 | $-0.66 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-20 | 0001558370-25-003386 | SEC ↗ |
| 2023-12-31 | 2024-03-28 | 0001558370-24-004246 | SEC ↗ |
| 2022-12-31 | 2023-03-30 | 0001558370-23-005127 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001558370-22-004958 | SEC ↗ |
| 2020-12-31 | 2021-04-15 | 0001558370-21-004356 | SEC ↗ |
| 2019-12-31 | 2020-03-30 | 0001558370-20-003385 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001558370-19-002192 | SEC ↗ |
| 2017-12-31 | 2018-03-20 | 0001558370-18-002275 | SEC ↗ |
| 2016-12-31 | 2017-03-21 | 0001558370-17-001962 | SEC ↗ |